The society for immunotherapy of cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma

Howard L. Kaufman; John M. Kirkwood; F. Stephen Hodi; Sanjiv Agarwala; Thomas Amatruda; Steven D. Bines; Joseph I. Clark; Brendan Curti; Marc S. Ernstoff; Thomas Gajewski; Rene Gonzalez; Laura Jane Hyde; David Lawson; Michael Lotze; Jose Lutzky; Kim Margolin; David F. McDermott; Donald Morton; Anna Pavlick; Jon M. Richards; William Sharfman; Vernon K. Sondak; Jeffrey Sosman; Susan Steel; Ahmad Tarhini; John A. Thompson; Jill Titze; Walter Urba; Richard White; Michael B. Atkins

doi:10.1038/nrclinonc.2013.153

The society for immunotherapy of cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma

Howard L. Kaufman, John M. Kirkwood, F. Stephen Hodi, Sanjiv Agarwala, Thomas Amatruda, Steven D. Bines, Joseph I. Clark, Brendan Curti, Marc S. Ernstoff, Thomas Gajewski, Rene Gonzalez, Laura Jane Hyde, David Lawson, Michael Lotze, Jose Lutzky, Kim Margolin, David F. McDermott, Donald Morton, Anna Pavlick, Jon M. RichardsWilliam Sharfman, Vernon K. Sondak, Jeffrey Sosman, Susan Steel, Ahmad Tarhini, John A. Thompson, Jill Titze, Walter Urba, Richard White, Michael B. Atkins

School of Medicine

Research output: Contribution to journal › Review article › peer-review

134 Scopus citations

Abstract

Immunotherapy is associated with durable clinical benefit in patients with melanoma. The goal of this article is to provide evidence-based consensus recommendations for the use of immunotherapy in the clinical management of patients with high-risk and advanced-stage melanoma in the USA. To achieve this goal, the Society for Immunotherapy of Cancer sponsored a panel of melanoma experts-including physicians, nurses, and patient advocates-to develop a consensus for the clinical application of tumour immunotherapy for patients with melanoma. The Institute of Medicine clinical practice guidelines were used as a basis for this consensus development. A systematic literature search was performed for high-impact studies in English between 1992 and 2012 and was supplemented as appropriate by the panel. This consensus report focuses on issues related to patient selection, toxicity management, clinical end points and sequencing or combination of therapy. The literature review and consensus panel voting and discussion were used to generate recommendations for the use of immunotherapy in patients with melanoma, and to assess and rate the strength of the supporting evidence. From the peer-reviewed literature the consensus panel identified a role for interferon-α2b, pegylated-interferon-α2b, interleukin-2 (IL-2) and ipilimumab in the clinical management of melanoma. Expert recommendations for how to incorporate these agents into the therapeutic approach to melanoma are provided in this consensus statement. Tumour immunotherapy is a useful therapeutic strategy in the management of patients with melanoma and evidence-based consensus recommendations for clinical integration are provided and will be updated as warranted.

Original language	English (US)
Pages (from-to)	588-598
Number of pages	11
Journal	Nature Reviews Clinical Oncology
Volume	10
Issue number	10
DOIs	https://doi.org/10.1038/nrclinonc.2013.153
State	Published - Oct 2013

ASJC Scopus subject areas

Oncology

Access to Document

10.1038/nrclinonc.2013.153

Cite this

Kaufman, H. L., Kirkwood, J. M., Hodi, F. S., Agarwala, S., Amatruda, T., Bines, S. D., Clark, J. I., Curti, B., Ernstoff, M. S., Gajewski, T., Gonzalez, R., Hyde, L. J., Lawson, D., Lotze, M., Lutzky, J., Margolin, K., McDermott, D. F., Morton, D., Pavlick, A., ... Atkins, M. B. (2013). The society for immunotherapy of cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nature Reviews Clinical Oncology, 10(10), 588-598. https://doi.org/10.1038/nrclinonc.2013.153

Kaufman, HL, Kirkwood, JM, Hodi, FS, Agarwala, S, Amatruda, T, Bines, SD, Clark, JI, Curti, B, Ernstoff, MS, Gajewski, T, Gonzalez, R, Hyde, LJ, Lawson, D, Lotze, M, Lutzky, J, Margolin, K, McDermott, DF, Morton, D, Pavlick, A, Richards, JM, Sharfman, W, Sondak, VK, Sosman, J, Steel, S, Tarhini, A, Thompson, JA, Titze, J, Urba, W, White, R & Atkins, MB 2013, 'The society for immunotherapy of cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma', Nature Reviews Clinical Oncology, vol. 10, no. 10, pp. 588-598. https://doi.org/10.1038/nrclinonc.2013.153

@article{3894fa0ee6524221936272034fb273b6,

title = "The society for immunotherapy of cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma",

abstract = "Immunotherapy is associated with durable clinical benefit in patients with melanoma. The goal of this article is to provide evidence-based consensus recommendations for the use of immunotherapy in the clinical management of patients with high-risk and advanced-stage melanoma in the USA. To achieve this goal, the Society for Immunotherapy of Cancer sponsored a panel of melanoma experts-including physicians, nurses, and patient advocates-to develop a consensus for the clinical application of tumour immunotherapy for patients with melanoma. The Institute of Medicine clinical practice guidelines were used as a basis for this consensus development. A systematic literature search was performed for high-impact studies in English between 1992 and 2012 and was supplemented as appropriate by the panel. This consensus report focuses on issues related to patient selection, toxicity management, clinical end points and sequencing or combination of therapy. The literature review and consensus panel voting and discussion were used to generate recommendations for the use of immunotherapy in patients with melanoma, and to assess and rate the strength of the supporting evidence. From the peer-reviewed literature the consensus panel identified a role for interferon-α2b, pegylated-interferon-α2b, interleukin-2 (IL-2) and ipilimumab in the clinical management of melanoma. Expert recommendations for how to incorporate these agents into the therapeutic approach to melanoma are provided in this consensus statement. Tumour immunotherapy is a useful therapeutic strategy in the management of patients with melanoma and evidence-based consensus recommendations for clinical integration are provided and will be updated as warranted.",

author = "Kaufman, {Howard L.} and Kirkwood, {John M.} and Hodi, {F. Stephen} and Sanjiv Agarwala and Thomas Amatruda and Bines, {Steven D.} and Clark, {Joseph I.} and Brendan Curti and Ernstoff, {Marc S.} and Thomas Gajewski and Rene Gonzalez and Hyde, {Laura Jane} and David Lawson and Michael Lotze and Jose Lutzky and Kim Margolin and McDermott, {David F.} and Donald Morton and Anna Pavlick and Richards, {Jon M.} and William Sharfman and Sondak, {Vernon K.} and Jeffrey Sosman and Susan Steel and Ahmad Tarhini and Thompson, {John A.} and Jill Titze and Walter Urba and Richard White and Atkins, {Michael B.}",

year = "2013",

month = oct,

doi = "10.1038/nrclinonc.2013.153",

language = "English (US)",

volume = "10",

pages = "588--598",

journal = "Nature Reviews Clinical Oncology",

issn = "1759-4774",

number = "10",

}

TY - JOUR

T1 - The society for immunotherapy of cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma

AU - Kaufman, Howard L.

AU - Kirkwood, John M.

AU - Hodi, F. Stephen

AU - Agarwala, Sanjiv

AU - Amatruda, Thomas

AU - Bines, Steven D.

AU - Clark, Joseph I.

AU - Curti, Brendan

AU - Ernstoff, Marc S.

AU - Gajewski, Thomas

AU - Gonzalez, Rene

AU - Hyde, Laura Jane

AU - Lawson, David

AU - Lotze, Michael

AU - Lutzky, Jose

AU - Margolin, Kim

AU - McDermott, David F.

AU - Morton, Donald

AU - Pavlick, Anna

AU - Richards, Jon M.

AU - Sharfman, William

AU - Sondak, Vernon K.

AU - Sosman, Jeffrey

AU - Steel, Susan

AU - Tarhini, Ahmad

AU - Thompson, John A.

AU - Titze, Jill

AU - Urba, Walter

AU - White, Richard

AU - Atkins, Michael B.

PY - 2013/10

Y1 - 2013/10

N2 - Immunotherapy is associated with durable clinical benefit in patients with melanoma. The goal of this article is to provide evidence-based consensus recommendations for the use of immunotherapy in the clinical management of patients with high-risk and advanced-stage melanoma in the USA. To achieve this goal, the Society for Immunotherapy of Cancer sponsored a panel of melanoma experts-including physicians, nurses, and patient advocates-to develop a consensus for the clinical application of tumour immunotherapy for patients with melanoma. The Institute of Medicine clinical practice guidelines were used as a basis for this consensus development. A systematic literature search was performed for high-impact studies in English between 1992 and 2012 and was supplemented as appropriate by the panel. This consensus report focuses on issues related to patient selection, toxicity management, clinical end points and sequencing or combination of therapy. The literature review and consensus panel voting and discussion were used to generate recommendations for the use of immunotherapy in patients with melanoma, and to assess and rate the strength of the supporting evidence. From the peer-reviewed literature the consensus panel identified a role for interferon-α2b, pegylated-interferon-α2b, interleukin-2 (IL-2) and ipilimumab in the clinical management of melanoma. Expert recommendations for how to incorporate these agents into the therapeutic approach to melanoma are provided in this consensus statement. Tumour immunotherapy is a useful therapeutic strategy in the management of patients with melanoma and evidence-based consensus recommendations for clinical integration are provided and will be updated as warranted.

AB - Immunotherapy is associated with durable clinical benefit in patients with melanoma. The goal of this article is to provide evidence-based consensus recommendations for the use of immunotherapy in the clinical management of patients with high-risk and advanced-stage melanoma in the USA. To achieve this goal, the Society for Immunotherapy of Cancer sponsored a panel of melanoma experts-including physicians, nurses, and patient advocates-to develop a consensus for the clinical application of tumour immunotherapy for patients with melanoma. The Institute of Medicine clinical practice guidelines were used as a basis for this consensus development. A systematic literature search was performed for high-impact studies in English between 1992 and 2012 and was supplemented as appropriate by the panel. This consensus report focuses on issues related to patient selection, toxicity management, clinical end points and sequencing or combination of therapy. The literature review and consensus panel voting and discussion were used to generate recommendations for the use of immunotherapy in patients with melanoma, and to assess and rate the strength of the supporting evidence. From the peer-reviewed literature the consensus panel identified a role for interferon-α2b, pegylated-interferon-α2b, interleukin-2 (IL-2) and ipilimumab in the clinical management of melanoma. Expert recommendations for how to incorporate these agents into the therapeutic approach to melanoma are provided in this consensus statement. Tumour immunotherapy is a useful therapeutic strategy in the management of patients with melanoma and evidence-based consensus recommendations for clinical integration are provided and will be updated as warranted.

UR - http://www.scopus.com/inward/record.url?scp=84885022736&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885022736&partnerID=8YFLogxK

U2 - 10.1038/nrclinonc.2013.153

DO - 10.1038/nrclinonc.2013.153

M3 - Review article

C2 - 23982524

AN - SCOPUS:84885022736

SN - 1759-4774

VL - 10

SP - 588

EP - 598

JO - Nature Reviews Clinical Oncology

JF - Nature Reviews Clinical Oncology

IS - 10

ER -

The society for immunotherapy of cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this